Blood News and Research

RSS

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Scientists have found that a synthetic molecule they designed can block activation of a gene in liver cancer cells, halting a process that allows some of those cancer cells to survive chemotherapy.

13 Oct 2010

HSV1716 clinical trial for childhood cancer receives FDA grant

A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S. Food and Drug Administration grant to support the research.

13 Oct 2010

CSL to distribute Cerus' INTERCEPT Blood System in Australia, New Zealand

Cerus Corporation announced today that it has entered into an agreement with CSL Limited, Biotherapies division to distribute Cerus' INTERCEPT Blood System for platelets in Australia and New Zealand. The INTERCEPT Blood System is designed to provide increased protection from a broad range of transfusion-transmitted pathogens, including bacteria and emerging pathogens such as the dengue and chikungunya viruses.

13 Oct 2010

Scientists identify mutant protein in type 2 diabetes

University of Michigan scientists have identified events inside insulin-producing pancreatic cells that set the stage for a neonatal form of non-autoimmune type 1 diabetes, and may play a role in type 2 diabetes as well. The results point to a potential target for drugs to protect normally functioning proteins essential for producing insulin.

13 Oct 2010

Cancer patients getting unnecessary tests: Study

US researchers revealed that many cancer patients with only a few years to live often continue to get routine mammograms or blood tests for prostate cancer even though they are not likely to live long enough to benefit from them. This not only wastes money but also exposes patients to unnecessary worry and distress.

12 Oct 2010

Smart for Life(R) to add Lepticore(R) to product line

Smart for Life(R), the trailblazing company featuring weight management products will begin adding Lepticore(R) to its product line this month.

12 Oct 2010

NCKU develops novel stem cell therapy for heart repair

Assistant Prof. Patrick C. H. Hsieh of Institute of Nanotechnology and Microsystems Engineering, College of Medicine, National Cheng Kung University (NCKU), Tainan, Taiwan, has led a research team of myocardial regeneration to conduct an experiment on pigs and has proved that by combining self-assembling peptide nanofiber hydrogel with autologous bone marrow stem cell, myocardial protection after acute myocardial infarction, vascular regeneration and heart functions can be improved.

12 Oct 2010

EMA approves TWYNSTA therapy that reduces BP in hypertensive patients

Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA. TWYNSTA is indicated for the treatment of hypertension in adults whose blood pressure is not adequately controlled on amlodipine or as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets containing the same component doses.

12 Oct 2010

Researchers investigate 'friendly bacteria' to kill bone cancer cells

Children and young people who are diagnosed with bone cancer could benefit from better treatment in the future thanks to new research at The University of Nottingham. The Bone Cancer Research Trust launches Bone Cancer Awareness Week today and has funded a new project at the University which is testing a theory that 'friendly bacteria' can be used to kill bone cancer cells.

12 Oct 2010

Behavioral management and preventive medication can combat migraine: Research

The combination of preventive medication and behavioral changes offered significant relief for 77 percent of the individuals enrolled in a study aimed at combating frequent, disabling migraine headaches, according to new Ohio University research published this week in the British Medical Journal.

12 Oct 2010

Study finds no link between AMD treatments and increase in cardiovascular complication

Newer treatments for age-related macular degeneration (AMD)-including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease-do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

12 Oct 2010

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

The number of Medicare recipients undergoing treatment for retinal conditions nearly doubled between 1997 and 2007, with significant shifts in the types of procedures most commonly performed, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

12 Oct 2010

Folic acid supplement does not reduce cardiovascular events, cancer or death

Use of folic acid supplements appears to lower blood levels of the amino acid homocysteine—theorized to be a risk factor for heart and blood vessel disease—but does not appear to be associated with reduced rates of cardiovascular events, cancer or death over a five-year period, according to a meta-analysis of previously published studies in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

12 Oct 2010

Essentialis receives patent for active component in DCCR product

Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR. Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

12 Oct 2010

Carotid artery stenting increases risk of death, stroke

For patients with blockages in the carotid artery that supplies blood to the brain, carotid artery stenting (a non-surgical treatment) appears to be associated with an increased risk of both short- and long-term adverse outcomes when compared with surgical treatment (carotid endarterectomy), according to a meta-analysis of previously published studies that was posted online today and will appear in the February 2011 print issue of Archives of Neurology, one of the JAMA/Archives journals.

12 Oct 2010

Study finds rapid increase in diabetes hospitalizations among young women

A study published in Journal of Women's Health shows a rapid increase in the number of hospitalizations due to diabetes for young adults - particularly young women.

12 Oct 2010

Insulin resistance increases risk of stroke in non-diabetic patients

Insulin resistance, a condition in which insulin produced by the body becomes less effective in reducing blood glucose levels, appears to be associated with an increased risk of stroke in individuals without diabetes, according to a report in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

12 Oct 2010

$Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer$

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

ZeroNines launches ZenVault Medical Personal Health Record portal

ZeroNines® Technology, Inc. announced the launch of ZenVault™ Medical, a Personal Health Record portal (PHR) that gives consumers instant, secure, private access to their medical records online. ZenVault Medical was specifically designed to address the public's concerns over data security, privacy, convenience, and expense associated with the national push to convert from traditional paper to digital medical records.

11 Oct 2010

Generex to acquire majority interest in Global Medical Direct

Generex Biotechnology Corporation today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications.

11 Oct 2010